European Medicines Agency recommends change in indication for cetuximab to RAS wild-type metastatic colorectal cancer

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product cetuximab (Erbitux). The CHMP changed the indication for use in metastatic colorectal cancer to clarify the particular genetic makeup of the cancer that must be present before treatment with Erbitux, which is described as epidermal growth factor receptor (EGFR)-expressing, RAS wild-type disease. Read more here.